The bill amends K.S.A. 2024 Supp. 65-4101 and K.S.A. 2024 Supp. 65-4111 to update definitions and classifications related to controlled substances in Kansas. Key changes include a revised definition of "administer," allowing patients or research subjects to apply controlled substances under a practitioner's direction without the practitioner being physically present. The term "medical care facility" is also clarified to align with existing definitions. Additionally, the bill provides a detailed list of substances classified under schedule IV, including specific drugs and their DEA codes, while introducing new definitions for terms such as "electronic prescription," "intermediary," and "ultimate user."

The bill further expands the classification of controlled substances by adding new drugs like oxazolam and paraldehyde, and it specifies regulations for materials containing lorcaserin and certain stimulants. Provisions regarding phentermine will expire once it is removed from Schedule IV of the federal controlled substances act. A notable aspect of the bill is the introduction of a process for the FDA approval of crystalline polymorph psilocybin, which, once certified by the Attorney General, will lead to the repeal of specific existing laws regarding psilocybin, marking a significant change in its legal status in Kansas. The act will take effect immediately upon publication in the statute book.

Statutes affected:
As introduced: 65-4101, 65-4111